Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Vella Bioscience Brings Precision to CBD With Pleasurewave™

Vella Bioscience Logo (PRNewsfoto/Vella Bioscience)

News provided by

Vella Bioscience

Apr 14, 2026, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Grounded in female arousal physiology, Vella's hero clinical‑grade arousal serum applies a more precise, performance‑led approach to CBD in intimate wellness

NEW YORK, April 14, 2026 /PRNewswire/ -- Though conversations around women's pleasure are slowly opening up, the gap between awareness and access remains. Most "solutions" designed to support the full continuum of desire, arousal, and pleasure - particularly amid hormonal change - have yet to catch up. Dialogue alone is not enough: women need real, reliable solutions that support the full continuum of desire, arousal, and pleasure. This is where Vella Bioscience, the pioneering female health company built to address long-overlooked gaps in women's sexual wellness, has focused its work. At the core of this mission is Pleasurewave™, Vella's first clinical-grade arousal serum, which applies a precise, biology-led approach to CBD to support the physiological realities of female pleasure.

Continue Reading
Vella Bioscience's Pleasurewave
Vella Bioscience's Pleasurewave

As CBD has become increasingly associated with intimacy, particularly among women navigating hormonal transition, Vella uses a science-led approach grounded in biological intent, formulation discipline, and transparency over trend. CBD is often discussed as a single ingredient, yet its form and composition vary widely. Full-spectrum extracts can fluctuate significantly in CBD concentration and include secondary compounds without consistent purpose. Pleasurewave is formulated using CBD isolate, a highly purified form of cannabidiol processed to remove all other cannabinoids, plant material, waxes, and terpenes, leaving behind only pure CBD. This allows Vella to formulate with greater consistency and control.

"We're at a moment where women are finally being invited into the conversation around pleasure, but they're still being underserved when it comes to solutions," said Carolyn Wheeler, Co-Founder and CEO of Vella Bioscience. "Pleasurewave was created to close that gap by giving women a more precise and reliable tool to support arousal and sensation, especially at times when their bodies may need more support."

Pleasurewave contains CBD isolate and it is stabilized through Vella's proprietary biotech liposome system (LPTv1) process which works to maintain its stability over time, reflecting the company's research-driven approach to formulation.

"Female arousal involves complex vascular and neurological processes," said Dr. Harin Padma-Nathan, Chief Medical Officer at Vella Bioscience. "Pleasurewave is designed to support these underlying mechanisms through targeted, localized delivery, helping enhance blood flow and sensory response where it matters most."

The CBD isolate used in Pleasurewave contains no detectable THC, directly addressing common concerns around drug testing, stigma, and psychoactive effects. Vella's position is clear: intimacy should feel intentional, not tentative.

Product Overview: Pleasurewave™

Pleasurewave ($55 MSRP) is a clinical-grade arousal serum engineered with Vella's patented liposomal delivery technology, designed to support female arousal through targeted, localized application, particularly when hormonal shifts impact blood flow, tissue responsiveness, and sensation.

Pleasurewave uses Vella's liposomal delivery system to encapsulate CBD isolate, enhancing skin penetration and enabling delivery to smooth muscle and nerve-dense structures within the clitoral network. This localized delivery supports vasodilation and sensory responsiveness: two important physiological components of arousal.

  • Nano-encapsulated CBD isolate is delivered to the smooth muscle beneath the skin, a critical but often overlooked aspect of arousal.
  • By supporting healthy blood flow and relaxing this tissue, Pleasurewave helps restore the body's natural rhythm of sensation
  • Free from cooling agents or numbing effects, the formula includes Vitamin E to soothe sensitive skin, monk fruit extract for antioxidant support, and a clean, oil-free, microbiome-friendly base designed for compatibility with condoms, toys, and daily intimacy.

In clinical studies, 90% of participants reported improvement in at least one aspect of sexual pleasure, particularly among women navigating perimenopause, menopause, stress, or other hormonal shifts.

"Pleasurewave plays a central role within the broader Vella portfolio," said Joy Allen-Altimare, President of Vella Bioscience. "It was designed to support a critical moment in a woman's experience when desire may be present, but the body needs assistance to respond. By offering targeted, reliable arousal support, Pleasurewave helps create greater confidence, connection, and ease in intimate experiences."

Vella's Pleasurewave is available at select premium retailers such as Lemon Laine, Cos Bar, Amazon and at www.vellabio.com.

About Vella Bioscience, Inc.
Vella Bioscience, Inc. is a female health innovator dedicated to advancing women's sexual, hormonal, and intimate wellness through rigorous science and proprietary biotechnology. Built on scientific rigor and developed by the same team behind Viagra® and Cialis®, Vella addresses critical gaps in women's health research with products designed to empower women through education and evidence-based care. The company launched the category-first Vella Pleasure Serum, giving women unprecedented agency over their sexual experiences through a science-backed, hormone-free approach. To learn more, visit www.vellabio.com.

MEDIA CONTACT: [email protected] 

SOURCE Vella Bioscience

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Vella Bioscience Reveals Bold Rebrand - An Unapologetic Approach to Championing Women's Sexual Vitality and Hormonal Wellness

Vella Bioscience Reveals Bold Rebrand - An Unapologetic Approach to Championing Women's Sexual Vitality and Hormonal Wellness

Vella Bioscience, a pioneering female health company advancing clinically driven solutions in women's hormonal, sexual, and intimate health, today...

Vella Bioscience Appoints Industry Innovator Joy Allen-Altimare as President, Accelerating a New Era of Femtech, Hormonal Health, and Science-Led Sexual Wellness

Vella Bioscience Appoints Industry Innovator Joy Allen-Altimare as President, Accelerating a New Era of Femtech, Hormonal Health, and Science-Led Sexual Wellness

Vella Bioscience, a pioneering FemTech company advancing clinically driven solutions in women's hormonal, sexual, and intimate health, today...

More Releases From This Source

Explore

Cannabis

Cannabis

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Women

Women

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.